Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2011-05-24
2011-05-24
Mertz, Prema (Department: 1646)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C435S235100, C435S320100, C435S325000
Reexamination Certificate
active
07947288
ABSTRACT:
The present invention relates to a novel fusion protein with the formula X-Y, or Y-X, wherein X represents a first immunoregulating polypeptide and Y represents a second immunoregulating polypeptide different from X. The present invention also relates to a nucleic acid molecule encoding such a fusion protein and a vector comprising such a nucleic acid molecule. The present invention also provides infectious viral particles and host cells comprising such a nucleic acid molecule or such a vector as well as a process for producing such infectious viral particles. The present invention also relates to a method for recombinantly producing such a fusion protein. Finally, the present invention also provides a pharmaceutical composition comprising such a fusion protein, a nucleic acid molecule, a vector, infectious viral particles and a host cell as well as the therapeutic use thereof.
REFERENCES:
patent: 5359035 (1994-10-01), Habermann
patent: 6552005 (2003-04-01), Buchsbaum et al.
patent: 198 23 351 (1998-12-01), None
patent: 0 158 198 (1985-10-01), None
patent: 0 225 579 (1987-06-01), None
patent: 0 288 809 (1988-11-01), None
patent: 0 816 510 (1998-01-01), None
patent: WO 93/20849 (1993-10-01), None
patent: WO 94/21792 (1994-09-01), None
patent: WO 98/08947 (1998-03-01), None
patent: WO 98/40498 (1998-09-01), None
patent: WO 99/36440 (1999-07-01), None
patent: WO 99/60128 (1999-11-01), None
patent: WO 00/53761 (2000-09-01), None
patent: WO 01/10912 (2001-02-01), None
patent: WO 01/68896 (2001-09-01), None
patent: WO 01/93898 (2001-12-01), None
patent: WO 02/22805 (2002-03-01), None
patent: WO 02/101049 (2002-12-01), None
patent: WO 02/102404 (2002-12-01), None
patent: WO 03/035105 (2003-05-01), None
patent: WO 03/048334 (2003-06-01), None
Bagriacik, Umit et al., “CD43 potentiates CD3-induced proliferation of murine intestinal intraepithelial lymphocytes,” 79(3) Immunology and Cell Biology 303-307 (Jun. 2001).
Bulfone-Paus, S et al., “Differential Regulation of Human T Lymphoblast Functions by IL2 and IL-15,” 9(7) Cytokine 507-513 (Jul. 1997).
Cao, Renhai et al., “Interleukin-18 acts as an angiogenesis and tumor suppressor,” 13 The FASEB Journal 2195-2202 (Dec. 1999).
Danthinne, X. et al., “Production of first generation adenovirus vectors: a review,” 7 Gene Therapy 1707-1714 (2000).
Dobmeyer, T. et al., “Mechanism of gamma sigma T-Cell-Mediated Inhibition of Stem Cell Differentiation in Vitro: Possible Relevance for Myelosuppression in HIV-Infected Individuals,” 184(1) Cellular Immunology (Feb. 25, 1998).
European Search Report dated Aug. 21, 2007 issued in European counterpart patent application 04 76 3359.
Gillies, Stephen D. et al., “Bi-functional cytokine fusion proteins for gene therapy and anti-body-targeted treatment of cancer,” 51 Cancer Immunol Immunothere. 449-460 (2002).
Hashimoto, Wataru et al., “Differential Antitumor Effects of Administration of Recombinant IL-18 or Recombinant IL-12 are Mediated Primarily by Fas-Fas Ligand- and Perforin-Induced Tumor Apoptosis, Respectively”, 163 The Journal of Immunology 583-589 (1999).
He, Z. et al., “Viral Recombinant Vaccines to the E6 and E7 Antigens of HPV-16,” 270 Virology 146-161 (2000).
International Search Report issued in corres. PCT/EP2004/008114, Mar. 31, 2005, EPO.
Ju, Dian Wen et al., “Adenovirus-mediated combined suicide gene and interleukin-2 gene therapy for the treatment of established tumor and induction of antitumor immunity,” 124(12) Journal of Cancer Research and Clinical Oncology 683-689 (1998).
Kaufmann, A.M., et al., “Comparison of Cytokines and CD80 for Enhancement of Immunogenicity of Cervical Cancer Cells,” 202(4) Immunobiology 339-352 (Oct. 2000).
Kim, Soo-Hyun et al., “Site-specific mutations in the mature form of human IL-18 with enhanced biological activity and decreased neutralization by IL-18 binding protein,” 98(6) Proc. Natl. Acad. Sci.3304-3309 (Mar. 13, 2001).
Kim, Soo-Hyun et al., “Identification of Amino Acid Residues Critical for Biological Activity in Human Interleukin-18,” 277(13) The Journal of Biological Chemistry 10998-11003 (Mar. 29, 2002).
Kondo, M., et al., “Enhancement of Interleukin-2-Induced Lymphokine-Activated Killer Activity by Interleukin 7 against Autologous Human Renal Cell Carcinoma,” 55(6) Oncology 588-593 (Nov. 1998).
Koyama, Fumikazu et al., “Combined suicide gene therapy for human colon cancer cells using adenovirus-mediated transfer of Escherichia coli cytosine deaminase gene and Escherichia coli uracil phosphoribosyltransferase gene with 5-fluorocytosine,” 7(7) Cancer Gene Therapy 1015-1022 (2000).
Ma, Averil et al., “The Pleiotropic Functions of Interleukin 15: Not So Interleukin 2-like After All,” 191(5) Journal of Experimental Medicine 753-755 (Mar. 6, 2000).
Micallef, Mark et al., “In vivoantitumor effects of murine interferon-γ-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites,” 43 Cancer Immunol Immunother 361-367 (1997).
Miller, Patrice et al., “Intratumoral Administration of Adenoviral Interleukin 7 Gene-Modified Dendritic Cells Augments Specific Antitumor Immunity and Achieves Tumor Eradication,” 11 Human Gene Therapy 53-65 (Jan. 2000).
Nakanishi, Kenji et al., “Interleukin-18 Regulates Both TH1 and TH2 Responses”, 19 Annu. Rev. Immunol. 423-474 (2001).
Osaki, T. et al., “Potent antitumor effects mediated by local expression of the mature form of the interferon-γ inducing factor, interleukin-18(IL-18),” 6 Gene Therapy 808-815 (1999).
Osaki, Tadashi et al., “IFN-γ-Inducing Factor/IL-18 Administration Mediates IFN-γ- and IL-12-Independent Antitumor Effects,” 160 The Journal of Immunology 1742-1749, (1998).
Ozdemir, Oner et al., “Interleukin-2 and Interleukin-15 Combination Induces Lymphokine Activated Killer Cells with Higher Perforin and Granzyme B Expression Patterns and Superior Cytotoxic Response Against Human Leukemia Cells,” 100(11) Blood (Nov. 16, 2002) and Abstract No. 1827, 44th Annual Meeting of the American Society of Hematology; Philadelphia, PA, USA (Dec. 6-10, 2002).
Rock, F. et al., “Overexpression and structure—function analysis of a bioengineered IL-2/IL-6 chimeric lymphokine,” 5(6) Protein Engineering 583-591 (Sep. 1992).
Shanafelt, Armen et al., “A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well toleratedin vivo,” 18(11) Nature Biotechnology 1197-1202, (Nov. 2000).
Slos, Philippe et al., “Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: Induction of CD8+T-cell immunity and NK activity,” 8(5) Cancer Gene Therapy 321-332 (2001).
Son, Young-Ik et al., “Interleukin-18(IL-18)Synergizes with IL-2 to Enhance Cytotoxicity, Interferon-γ Production, and Expansion of Natural Killer Cells,” 61(3) Cancer Research 884-888 (Feb. 1, 2001).
Vaquez, Nancy et al., “Interleukin-15 Augments Superoxide Production and Microbicidal Activity of Human Monocytes against Candida albicans,”66(1) Infection and Immunity 145-150 (Jan. 1, 1998).
Wang, Q. et al., “Intratumoral IL-18 gene transfer improves therapeutic efficacy of antibody-targeted superantigen in established murine melanoma,” 8(7) Gene Therapy 542-550 (Apr. 2001).
Wigginton, Jon et al., “Synergistic Engagement of an Ineffective Endogenous Anti-Tumor Immune Response and Induction of IFN-γ and FAS-Ligand-Dependent Tumor Eradication by Combined Administration of IL-18 and IL-2,” 169(8) The Journal of Immunology 4467-4474 (Oct. 15, 2002).
Buchanan & Ingersoll & Rooney PC
Mertz Prema
Transgene S.A.
LandOfFree
Viral particles encoding multifunctional cytokines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Viral particles encoding multifunctional cytokines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Viral particles encoding multifunctional cytokines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2665584